Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06405100 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 8, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in patients with MCD.
Trial Details
NCT Number NCT06405100
Lead Sponsor Air Force Military Medical University, China
Collaborators: First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, The Second Affiliated Hospital of Air Force Military Medical University, Shaanxi Provincial People's Hospital, Shaanxi Provincial Hospital of Chinese Medicine
Conditions
(from sponsor)		 Minimal Change Disease
Related terms Nephrosis, Lipoid
Enrollment 81 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov